JASPER THERAPEUTICS, INC. Operating Lease Liability
JASPER THERAPEUTICS, INC. (JSPR) had Operating Lease Liability of $270.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability $270.00K.
- 2026-03-31: Operating Lease, Liability $757.00K.
- 2025-12-31: Operating Lease, Liability $1.24M.
- 2025-09-30: Operating Lease, Liability $1.70M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $270.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $757.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $1.24M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $1.70M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $2.15M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $2.59M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $1.81M 10-K · filed 2025-02-28 | |
| 2024-09-30 | $2.07M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.32M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $2.55M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $2.79M 10-K · filed 2024-03-05 | |
| 2023-09-30 | $3.01M 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $1.09M 10-K · filed 2023-03-08 | |
| 2022-09-30 | $3.85M 10-Q · filed 2022-11-10 | |
| 2021-12-31 | $760.00K 10-K · filed 2023-03-08 | $3.00M 10-Q · filed 2021-11-12 |
| 2020-12-31 | $485.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |